Piper Sandler Maintains Overweight on AVITA Medical, Raises Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien has maintained an Overweight rating on AVITA Medical (NASDAQ:RCEL) and raised the price target from $18.5 to $23.
August 11, 2023 | 4:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler's raised price target for AVITA Medical suggests a positive outlook for the company's stock.
The raised price target by Piper Sandler indicates their belief in the company's potential for growth. This could lead to increased investor confidence and a potential rise in AVITA Medical's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100